KYTHERA Biopharmaceuticals has closed a $37.4M Series D financing round. The round featured significant new investments as well as participation from all existing institutional investors. Proceeds from this financing are slated to be used for conducting US phase III trials for KYTHERA's lead product, ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental fat.
KYTHERA's investors include Versant Ventures, ARCH Venture Partners, Prospect Venture Partners, JAFCO, Partner Funds management (PFM), INVUS Financial Advisors, BBT Capital Management/Apothecary Capital, and Altitude Life Science Ventures. Also joining the syndicate were Foley Ventures and Latham and Watkins. KYTHERA has now raised more than $108M in four rounds of private financing.